CJC-1295 & Ipamorelin for Growth Hormone Support CJC-1295 is a growth hormone support therapy that addresses various hormonal concerns, such as sleep patterns and body fat distribution
Phase 2 RCT in The Lancet : at 24 weeks, tesofensine 0.5 mg produced a mean diet-adjusted weight loss of 9.2%, and at 1.0 mg a loss of 10.6%, compared with 2.0% for diet plus placebo (p 99% (HPLC, LCMS) Documentation: Batch-specific Certificate of Analysis (COA) included Handling for Research Use Tesofensine capsules ship as a pre-encapsulated, dry oral-research format
doi: 10.1016/0003-9861(52)90042-8 101 MiddletonE
Tissue quality is often higher with the blend: better mechanical properties, improved cellular organization, less scarring, and function closer to the original tissue
However, these increases were time dependent, and the levels returned to normal after about 1 month